Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad’s Droplet Digital™ PCR Technology Proves Instrumental in Developing a Functional Cure for HIV

Published: Thursday, November 01, 2012
Last Updated: Thursday, November 01, 2012
Bookmark and Share
The QX100™ Droplet digital system enables Sangamo BioSciences to accurately detect rare mutations.

Bio-Rad Laboratories, Inc. announced that its QX100 Droplet Digital PCR (ddPCR™) system enabled researchers at Sangamo BioSciences, Inc. to generate highly precise and reproducible data that puts the company one step closer to identifying a functional cure for HIV.

“The QX100 system allowed us to easily, accurately, and reproducibly measure low-copy events in genomic DNA,” said Dr. Gary Lee, senior scientist at Sangamo BioSciences. “ddPCR technology gave us confidence in our results, which is critical in advancing any program.”

Sangamo BioSciences utilizes a proprietary zinc-finger DNA-binding protein (ZFP) technology to modify the CCR5 gene, which encodes a major cell-surface co-receptor used by HIV to enter and infect CD4+ cells. The company engineered gene-editing ZFP nucleases (ZFNs) to permanently disrupt CCR5 in the immune cells (CD4+ T-cells) of HIV-positive (HIV+) patients, making these cells resistant to infection and thus potentially able to control the virus upon re-infusion into the patient. This revolutionary treatment employs each patient’s own immune cells as an alternative to drug therapy.

Available data from HIV+ subjects in trials to date suggest that integration of HIV DNA into the host cell's genome is a rare event, occurring in only one cell per 1,000–100,000 CD4+ T-cells in peripheral blood. This apparently low level of HIV DNA in the CD4 compartment is known to sustain a low level of viral replication, especially in lymphoid tissues, even when free virus in the periphery has been eliminated by drug therapy. Therefore, one of the major challenges in Sangamo’s research was to determine a way to measure the level of HIV DNA in a subject and thereby evaluate the effectiveness of the new therapy. Although real-time quantitative PCR (qPCR) is an effective technology for gene expression analysis, imperfect amplification efficiencies and the necessity of establishing a standard curve prevent qPCR from delivering the precision and sensitivity needed to detect rare target DNA sequences.

Droplet Digital PCR technology provides an absolute measure of target DNA and RNA molecules, offering far greater sensitivity, reproducibility, and precision than qPCR. The QX100 system partitions samples and reagents into 20,000 droplets, with target and background DNA randomly distributed among them. This partitioning reduces background interference, allowing for more reliable and sensitive measurement of single copies of a target sequence (with abundances as low as 0.0001% of background) within a complex sample. Due to the digital nature of the assay and the fact that no standard curve is required, ddPCR can discriminate differences in target DNA concentrations as low as 10%.

According to Dr. Lee, at low copy numbers in two separate assays, real-time PCR results indicated a tenfold difference, making it difficult to determine whether the data reflected experimental variation or biological reality. With ddPCR technology, the difference was shown to be only twofold.

“That’s data we can really trust,” said Lee.

The company is currently conducting two phase 2 clinical trials in HIV+ patients. The QX100 system will be instrumental in allowing Sangamo BioSciences to determine the effectiveness of its therapy in reducing HIV levels. Thus far, the clinical data demonstrate a statistically significant relationship between the number of modified T-cells and a reduction in viral load during an interruption of antiviral treatment.

“We have been able to demonstrate that the QX100 system is the technology of choice when it comes to rare-event detection applications, particularly in clinical studies,” said Dr. Lee.

For further details about the QX100 Droplet Digital PCR system, please visit http://bit.ly/ddPCR_QX100 . To learn more about how Sangamo scientists employed ddPCR to measure the efficacy of their functional cure, please read the story at http://bit.ly/Sangamo_Story.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Presentations at the AACR Annual Meeting to Highlight Advances in Cancer Research Made Possible by Bio-Rad’s Droplet Digital™ PCR Technology
Tailoring Treatments and Tracking Mutations with Liquid Biopsies possible with ddPCR™ technology
Wednesday, April 22, 2015
Bio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results
Company has introduced its S3e™ Cell Sorter during the quarter.
Saturday, March 07, 2015
Accurate Determination of Copy Number States for Multiallelic Copy Number Variations
Researchers use next-generation sequencing (NGS) and Bio-Rad’s Droplet Digital PCR (ddPCR™) technology to solve the technical challenge.
Tuesday, March 03, 2015
Awards for Bio-Rad's Protein Expression Products and Genomic Workflow Solutions
BioInformatics LLC has recognized Bio-Rad with two prestigious Life Science Industry Awards for “Best Protein Expression & Analysis Products” and “Best Workflow Solutions — Genomics.”
Monday, January 19, 2015
Quantitative Western Blotting Using Stain-Free Technology
Bio-Rad hosted two seminars at the EB 2014 in which KOLs discussed approaches to improve the accuracy of western blotting quantitation using Bio-Rad’s stain-free technology.
Friday, September 05, 2014
Bio-Rad Acquires Sequencing Technology Company GnuBIO
GnuBIO is a privately-held life sciences company that has developed a droplet-based DNA sequencing technology.
Friday, April 11, 2014
Royal Canadian Mounted Police to Use Bio-Rad’s KnowItAll® Spectroscopy Software for Analysis of Automobile Crime Scene Samples
Using the KnowItAll software to search multiple automobile paint layers found at a crime scene against the PDQ database, forensic scientists can determine the make, model, year, and manufacturing origin of the samples.
Sunday, March 30, 2014
Bio-Rad Partners with the U.S. Pharmacopeial Convention
Company announces the availability of a beta version of the USP Spectral Library™ for raw material identification in the food and drug industries.
Thursday, March 06, 2014
Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
A Brief RT-qPCR “Field Guide” for MIQE Adherence
Bio-Rad’s Sean Taylor and Eli Mrkusich have published a practical guide for MIQE compliance.
Monday, December 09, 2013
Accurate Detection of Extremely Rare Mitochondrial DNA Deletions Associated with Aging
The study published in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging.
Thursday, September 05, 2013
Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
Accurate Quantification of NGS Libraries
A study has found that Droplet Digital PCR (ddPCR™) can be used as an accurate and precise method for quality control of NGS libraries.
Tuesday, August 20, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Producing Reliable Quantitative Western Blot Data
The reporting of fold changes in protein expression from western blots is often viewed with skepticism due to questions about the validity of the technique as a quantitative method.
Monday, June 17, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!